Peptide education
Cartalax
Kartalax · AED · T-31 · Ala-Glu-Asp · alanyl-glutamyl-aspartic acid
Cartalax is a three-amino-acid peptide, Ala-Glu-Asp, built around a cartilage story. In Russia it is an oral supplement listed as an additional peptide source; in English-language shops it is a 10 to 20 mg research vial marketed for joints, recovery, wound healing, and anti-aging. The cartilage interest has a real laboratory basis: a 2023 rat study showed AED pushing chondrocyte proliferation in culture. What it does not have is a modern human trial, and even the old human reports on this page describe no radiographic cartilage change.
Cartalax has a defined sequence and a plausible cartilage-cell rationale, and that is roughly where the support ends. The human record is three inconsistent retellings of one old dataset, and the sellers' cartilage-regrowth language is a claim the page's own sources undercut.
Overview
Quick answer
Russian oral Cartalax, old Russian-center clinical reports, and English research vials all use the name, but they are not the same evidence. One set describes oral-course history, another gives weak symptom reports, and another sells vials with identity and sterility questions. The materials use different forms, stated amounts, regulatory categories, and even some conflicting sequence and CAS details.
What is Cartalax?
Alanyl-glutamyl-aspartic acid: a defined tripeptide also written Ala-Glu-Asp or AED. PubChem and Russian reference material agree on that identity; some vendor listings describe it differently, which is the first warning sign on this page.
Why is it discussed?
Because cartilage is a problem people want a capsule for. Cartalax is marketed around osteoarthritis, osteochondrosis, osteoporosis, rehabilitation, wound healing, and anti-aging. The interest is understandable; the evidence behind it is cell studies plus small, old, mutually contradictory human reports.
What routes and amounts show up?
The Russian materials are oral: the brochure describes 1 to 3 tablets 2 to 3 times daily before food for 30 to 45 days, and its recommendation section describes 2 capsules 3 times daily for 45 days in osteoarthritis or osteochondrosis, and 2 capsules twice daily for 30 days in osteoporosis. English vendors sell 10 to 20 mg research vials, and no source on this page documents a human regimen for those.
How strong is the evidence?
Weak. The best direct support is a rat chondrocyte study; the human material is a 2011-era brochure, a lecture summary, and a vendor retelling that disagree on patient counts and response percentages. Cartilage regrowth would need structural human evidence, and the old reports themselves note no radiographic change.
Reported practice
Commonly reported protocol
Russian oral supplement courses. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
A rat chondrocyte study reported that AED increased chondrocyte numbers in primary cultures from young and old animals. That supports a laboratory rationale, not a human cartilage-repair outcome.
The available human material describes symptom-focused improvements in osteoarthritis and osteochondrosis, but methods are sparse, documentation is limited, and later summaries disagree on patient counts and percentages.
The RLS entry lists Cartalax as a biologically active supplement and frames it as an additional peptide source. That is not the same as FDA drug approval or evidence that research vials match the Russian oral product.
English sellers use the Cartalax name for research vials and health claims, while public identity, CAS, COA, sterility, and formulation details are inconsistent across listings.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Cartalax is a cartilage peptide. | Human sources discuss osteoarthritis, osteochondrosis, and osteoporosis, but they are older, small, and poorly documented by modern trial standards. | The most direct support is the rat chondrocyte paper reporting increased chondrocyte proliferation with AED, plus related short-peptide literature on proliferation, apoptosis, and gene-expression markers. | Russian retail and institute-linked material keeps Cartalax centered on joints and cartilage. English vendor pages repeat that theme while adding broader recovery and anti-aging claims. | The identity and cartilage-research interest are fair, but human cartilage rebuilding goes beyond the evidence. |
| Cartalax improves osteoarthritis symptoms. | The legacy clinical brochure describes 33 treated patients and 31 controls across knee osteoarthritis, osteochondrosis, and osteoporosis, with osteoarthritis symptom improvement reported in 68.5% and no meaningful short-term radiographic change. A lecture summary and a vendor summary report different cohort details and percentages. | Chondrocyte proliferation and cartilage-cell marker papers make joint interest plausible. No blinded, adequately powered osteoarthritis trial with standard pain and function measures has surfaced. | Current market pages and Russian summaries keep repeating joint-pain and mobility themes, which helps explain search interest while leaving efficacy unsettled. | The evidence provides a weak historical symptom signal. It is not enough to make Cartalax a confirmed osteoarthritis treatment. |
| Cartalax rebuilds or regenerates cartilage in humans. | The available human summaries lack a strong structural cartilage outcome. The older summaries specifically note no significant radiographic change during the reported observation period. | In vitro chondrocyte proliferation is relevant to cartilage biology, but repaired cartilage tissue, slowed joint-space loss, and disease modification need human structural outcomes. | Vendor copy often stretches from cartilage interest into repair language. That is marketing language, not a demonstrated human structural endpoint. | The evidence supports cartilage-oriented discussion, not a human cartilage-regeneration claim. |
| Cartalax helps osteoporosis or bone health. | Osteoporosis appears in the legacy clinical brochure and vendor retellings, but the available human documentation is too limited and inconsistent for a dependable osteoporosis claim. | Osteoporosis-related abstract and animal material give the claim a preclinical basis rather than a confirmed human treatment basis. | Russian and vendor materials sometimes group osteoporosis with osteoarthritis and osteochondrosis under musculoskeletal support. | This remains preclinical plus legacy-report context. Bone-density and fracture-risk claims would need better human evidence. |
| Cartalax is an anti-aging or longevity peptide. | Human evidence is not strong enough to call Cartalax a longevity or healthy-aging intervention. | Short-peptide papers discuss gene expression, proliferation, apoptosis, mesenchymal stem cells, fibroblasts, kidney cells, and peptide-DNA interactions. Those mechanisms explain why anti-aging claims appear, but a human longevity outcome has not been shown. | English vendor listings and peptide-market pages commonly attach anti-aging or recovery claims to Cartalax, often beside other repair peptides. | The anti-aging claim rests on market discussion and mechanism; a human anti-aging benefit has not been shown. |
| Cartalax is safe because legacy reports showed no side effects. | The legacy brochure says Cartalax was well tolerated, with no side effects or dependence in the observed cohort. That is reassuring only within a small, older, low-visibility report. | Mechanism papers discuss lowering p53 and increasing proliferative markers such as PCNA. That may be relevant to repair hypotheses, but it is not a safety guarantee. | Research-vial and supplement listings can make Cartalax sound gentle because it is a short peptide. Unauthorized injectable peptide warnings and compounding-risk discussions point in the other direction for non-approved vial use. | Short-term tolerability claims are too limited for broad safety language. Route, formulation, sterility, immune response, impurities, and long-term biology remain important unknowns. |
Bottom line
Main takeaway
Cartalax is a real peptide with a cartilage research story, but the promises are ahead of the data. The support is cell cultures and small old reports, not a modern joint-repair trial.
The Russian oral supplement and the English research vial are different product worlds, with different forms, amounts, and quality controls. Treat vendor cartilage claims as marketing until identity, testing, and human data line up.
Work from PubChem identity, the RLS supplement listing, the 2023 chondrocyte paper, and the legacy clinical documents, then watch how quickly the summaries start contradicting each other on cohorts and percentages. That contradiction is the finding.
Identity
What it is
Cartalax is Ala-Glu-Asp, a tripeptide of alanine, glutamic acid, and aspartic acid. It comes from the Khavinson bioregulator lineage, which assigns short peptides to target organs; this one was assigned to cartilage.
The evidence forms a ladder with a missing top rung. The lower rungs are solid for what they are: a defined sequence, a Russian supplement listing, and a 2023 rat study showing AED increased chondrocyte numbers in culture, with larger effects in cells from older animals. The human rung is a 2011-era brochure reporting symptom improvement in small osteoarthritis and osteochondrosis cohorts with no radiographic change, plus two later summaries that give different cohort sizes and different percentages for what should be the same data. The top rung, a modern randomized trial with validated pain, function, or structural endpoints, does not exist.
The market adds an identity problem on top. Listings drift between Ala-Glu-Asp and Ala-Glu-Asp-Lys, CAS numbers conflict, and COA snippets vary in depth, so "Cartalax" on a vial label is not yet a verified identity.
How people talk about it online
Russian retail and institute-linked pages keep Cartalax where the legacy documents put it: joints, cartilage, osteoarthrosis, osteochondrosis, osteoporosis, and rehabilitation.
English peptide sellers move it into 10 to 20 mg research vials and add wound-healing, recovery, and anti-aging language. None of those listings documents a human regimen or a verified match to the Russian oral product.
The usual forum layer is thin here: the collected material shows no consistent Reddit-style pattern of routes, amounts, and outcomes. What dominates the search results is vendor positioning.
Use context
Routes, doses, and cycle patterns
Cartalax use-pattern language comes mostly from Russian supplement and legacy clinical materials, not from a modern FDA label or contemporary randomized trial. The concrete numbers are oral tablet or capsule schedules in older documents. English research-vial listings commonly show 10 to 20 mg vials, but these sources do not document a human injectable or research-vial regimen.
Human studies and product labels
RLS Russian supplement listing
- Purpose
- Additional source of peptides
- Context
- Russian reference listing for a biologically active supplement
- Route
- Oral
- Amount
- RLS excerpt does not report a usable amount
- Frequency
- RLS excerpt does not report a usable schedule
- Duration
- RLS excerpt does not report a usable course length
The RLS entry is narrow: Cartalax is listed as a supplement, not as a conventional drug approval. This supports identity and regulatory context more than it supports therapeutic efficacy.
Legacy clinical testing regimen
- Purpose
- Osteoarthritis, osteochondrosis, and osteoporosis symptom reports
- Context
- 2011 company-linked clinical brochure
- Route
- Oral tablets
- Amount
- 1 to 3 tablets
- Frequency
- 2 to 3 times daily, 10 to 15 minutes before food
- Duration
- 30 to 45 days depending on severity
The brochure describes symptoms, routine labs, biochemistry, and radiography, but it lacks enough modern trial detail to judge randomization, blinding, standard instruments, allocation concealment, or statistical methods.
Legacy recommendation section after the study
- Purpose
- Historical disease-specific oral-course suggestions
- Context
- 2011 company-linked brochure recommendation text
- Route
- Oral capsules
- Amount
- 2 capsules per dose
- Frequency
- OA/osteochondrosis: 3 times daily; osteoporosis: 2 times daily
- Duration
- OA/osteochondrosis: 45 days; osteoporosis: 30 days; repeat courses every 3 to 6 months
This is historical product-document language, not independent dose validation. It preserves the reported schedule.
Lecture summary of osteoarthritis use
- Purpose
- Knee osteoarthritis symptom discussion
- Context
- Secondary lecture summary of older OA use
- Route
- Oral capsules
- Amount
- Stage- and age-based plan ranging from 1 capsule twice daily up to 6 capsules daily
- Frequency
- Twice daily to divided daily dosing depending on the summarized plan
- Duration
- 20 days
The lecture summary reports symptom reduction in 55% to 63% of cases and no significant radiologic change, but it is a secondary source and does not line up cleanly with other Cartalax summaries.
Vendor retelling of clinical use
- Purpose
- OA, osteochondrosis, and osteoporosis marketing context
- Context
- Current vendor clinical-trials summary
- Route
- Oral capsules
- Amount
- 1 to 2 capsules
- Frequency
- 2 to 3 times daily during meals
- Duration
- 20 to 30 days; repeated yearly courses described for osteoporosis
The vendor summary shows how Cartalax is marketed now, but it conflicts with other summaries on patient counts and percentages.
Real-world discussion
Russian oral supplement courses
- Purpose
- Joint and cartilage discussion
- Context
- Russian retail and institute-linked supplement materials
- Route
- Oral tablets or capsules
- Amount
- 1 to 3 tablets 2 to 3 times daily before food in brochure language
- Frequency
- Two to three times daily before food
- Duration
- 30 to 45 day courses in the brochure pattern
The collected material shows no consistent Reddit-style pattern of routes, amounts, and outcomes, and English research-vial listings do not document a human injectable regimen. Reported as context, not a recommendation.
What varies
- Product context: Russian oral supplement material describes capsule or tablet course claims; English research-vial listings mostly show vial size, marketing claims, and quality-document gaps.
- Route: oral tablet or capsule schedules in legacy documents are separate from vial-use discussions.
- Amount: historical capsule/tablet counts and vendor vial milligrams are not dose-equivalent units.
- Identity: Ala-Glu-Asp, Ala-Glu-Asp-Lys, and conflicting CAS descriptions are not the same confirmed product.
- Quality: COA snippets, purity claims, sterility, endotoxin, peptide content, and lot representativeness need separate review.
Human data
Human evidence
Thin, old, and internally inconsistent. The 2011-era brochure describes 33 treated patients and 31 controls, with osteoarthritis symptom improvement reported in 68.5% and no meaningful short-term radiographic change. A lecture summary reports 55% to 63% symptom reduction over a 20-day plan, and a vendor retelling reports 72.6% and 65.3% for what should be overlapping data. Three versions of one small record that do not agree on the numbers cannot carry a cartilage-repair claim, and none of them reports a structural cartilage outcome.
Evidence maturity
Cartalax's human evidence is small, old, and inconsistent; cartilage-regeneration claims run far ahead of it.
Rat chondrocyte proliferation work and broader short-peptide gene-expression papers supply the cartilage rationale.
A 2011-era Russian brochure and later retellings report symptom improvement in small osteoarthritis cohorts, with no short-term radiographic cartilage change.
No modern randomized trial with validated pain, function, or structural cartilage endpoints has been published.
A Russian supplement listing and English gray-market vials carry the claims, with conflicting identity and CAS details.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Legacy Cartalax clinical brochure | 33 treated patients and 31 controls across knee osteoarthritis, osteochondrosis, and osteoporosis; ages 45 to 78 in the cited summary. | Legacy clinical report from company-linked material | Russian oral Cartalax product context | Osteoarthritis symptom improvement was reported in 68.5%, osteochondrosis pain reduction in 53.7%, and no meaningful short-term radiographic change was described. | The available text lacks modern details on randomization, blinding, standard pain scales, allocation concealment, statistical methods, or adverse-event tables. | Weak human evidence |
| Linkova lecture summary of older OA use | Knee osteoarthritis patients described as ages 52 to 72 | Secondary lecture summary | Russian oral Cartalax product context | The summary describes a 20-day stage-based plan and reports symptom reduction in 55% to 63% of cases, with no significant radiologic change during the period. | It is not the original trial report, and its cohort details and response percentages diverge from the brochure. | Weak human evidence |
| Current vendor clinical-trials summary | 63 patients described across OA, osteochondrosis, and osteoporosis | Marketing summary | Vendor retelling of Cartalax clinical use | The vendor material reports OA symptom improvement at 72.6% and osteochondrosis pain reduction at 65.3%. | This is a marketing source, not an independently confirmed clinical paper, and the numbers conflict with other summaries. | Anecdotal or marketing-supported human claim |
| Rat chondrocyte AED study | Primary chondrocyte cultures from young and old rats | Preclinical cell study | Laboratory AED exposure | AED at 200 ng/mL increased chondrocyte numbers by roughly 1.4 to 1.8 times in cultures from young rats and 1.6 to 2.1 times in cultures from old rats. | Cell-culture proliferation cannot show clinical cartilage repair, symptom improvement, dosing, or safety in humans. | Preclinical |
Cautions
Safety and unknowns
- Modern human safety data are limited. The legacy brochure's tolerability statement cannot substitute for larger adverse-event studies, long-term follow-up, or route-specific safety information.
- Mechanism papers that discuss lowering p53 and increasing PCNA are biologically relevant, but those markers are not a safety guarantee.
- Research-vial use raises sterility, endotoxin, peptide-content, residual-solvent, degradation, shipping, and lot-representativeness questions outside what oral supplement documents can settle.
- Unauthorized injectable peptide warnings and compounding-risk discussions are not Cartalax-specific harm reports, but they are relevant to gray-market vial risk.
Product quality
A vial label is only a starting point
Cartalax has unusual identity and comparability problems: PubChem and RLS align around Ala-Glu-Asp, while some market material uses conflicting amino-acid or sequence descriptions.
CAS numbers and sequence labels drift across vendors, including a listing that describes Ala-Glu-Asp-Lys rather than Ala-Glu-Asp.
Public COA language is inconsistent. A purity percentage or LCMS/HPLC snippet can still leave sterile manufacturing, concentration accuracy, endotoxin control, and shipment stability unknown.
Identity
A tripeptide and a tetrapeptide listing point to different Cartalax identities unless independent testing reconciles the label.
Form and route
Oral tablets or capsules in Russian materials leave research-vial products and injected use unconfirmed.
COA depth
Purity, identity, peptide content, sterility, endotoxin, residual solvents, degradation products, and lot sampling answer different quality questions.
Comparability
A market vial, a supplement listing, a legacy brochure product, and a patent method may not represent the same manufacturing or quality system.
Mechanism
How it is proposed to work
Cartalax is proposed to influence cartilage-cell and tissue-repair biology through short-peptide effects on cell proliferation, apoptosis-related markers, and gene-expression regulation. That makes the joint-repair interest understandable, but the mechanism is still far upstream from showing that a product repairs human cartilage.
The most direct cartilage study reported AED effects in rat chondrocyte cultures, including larger relative proliferation effects in cells from older animals.
Khavinson-network and related papers discuss PCNA, p53, kidney cells, skin fibroblasts, mesenchymal stem cells, and short-peptide modulation of gene expression.
Peptide-DNA interaction papers support a broad plausibility argument for short peptides, but Cartalax dosing, clinical efficacy, and long-term safety have not been shown.
Cartalax (Ala-Glu-Asp) is a tripeptide from the Khavinson bioregulator lineage, positioned for cartilage based on the lineage's organ-specific short-peptide framework. Preclinical work reports effects on chondrocyte proliferation; the gene-expression-modulation framing common to the lineage applies here.
FAQ
Common questions
Does Cartalax work for joints?
The human evidence is legacy Russian material — an old clinical brochure, lecture summaries, and vendor retellings — plus preclinical chondrocyte work. There are no controlled trials that would meet modern standards, so the cartilage claims rest on lineage literature.
What do community protocols look like?
The documented patterns are oral: the Russian brochure describes 1 to 3 tablets 2 to 3 times daily before food for 30 to 45 days. The collected material shows no consistent community injection protocol.
Is Cartalax the same as other Khavinson bioregulators?
It belongs to the same lineage — short synthetic peptides developed from organ extracts — but each is a distinct molecule. Cartalax is Ala-Glu-Asp, a tripeptide positioned for cartilage, and vendor listings sometimes drift on the exact sequence.
Details
Technical details
Sources
References
- 1.
PubChem. PubChem compound record for Cartalax 2026.
Accessed 2026-06-14.
Supports Ala-Glu-Asp identity, formula, molecular weight, and synonym context.
- 2.
RLS. RLS Cartalax supplement entry 2026.
Accessed 2026-06-14.
Supports Russian biologically active supplement status and narrow peptide classification.
- 3.
Vrach. Effect of short peptides on rat chondrocyte proliferation 2023.
Accessed 2026-06-14.
Supports preclinical AED chondrocyte proliferation claims.
- 4.
Other. Cartalax clinical brochure section 2011.
Accessed 2026-06-14.
Supports legacy oral Cartalax regimen, symptom-improvement reports, tolerability wording, and radiographic caveats.
- 5.
Other. Linkova lecture summary of older Cartalax musculoskeletal use
Accessed 2026-06-14.
Supports secondary OA regimen and response-percentage summary.
- 6.
Other. Vendor clinical-trials summary for Cartalax
Accessed 2026-06-14.
Supports current marketing retelling and conflicting human-evidence percentages.
- 7.
Other. English-language Cartalax vendor vial listings
Accessed 2026-06-14.
Supports 10 to 20 mg research-vial market context and joint, wound-healing, recovery, and anti-aging claim language.
- 8.
Other. Cartalax vendor sequence and CAS-number drift examples
Accessed 2026-06-14.
Supports Ala-Glu-Asp versus Ala-Glu-Asp-Lys and CAS-number inconsistency warnings.
- 9.
Other. Public Cartalax COA and purity snippets
Accessed 2026-06-14.
Supports inconsistent public COA depth and purity-testing caveats.
- 11.
FDA. FDA peptide compounding risk context
Accessed 2026-06-14.
Supports immunogenicity, impurity, API-characterization, and sterile product-quality concerns for peptide products.
- 12.
PubMed. Short-peptide gene-expression and cell-aging literature
Accessed 2026-06-14.
Supports PCNA, p53, proliferation, apoptosis, fibroblast, kidney-cell, MSC, and short-peptide mechanism context.
- 13.
PubMed. Short peptides and dsDNA-binding mechanism paper 2019.
Accessed 2026-06-14.
Supports broad plausibility of peptide-DNA interaction mechanisms without establishing Cartalax efficacy.
- 14.
PubMed. Cartalax osteoporosis-related abstract or animal-model source
Accessed 2026-06-14.
Supports preclinical or abstract-level osteoporosis context.
- 15.
Other. Russian patent material describing Cartalax in a complex musculoskeletal treatment method
Accessed 2026-06-14.
Supports intramuscular-use mention inside a multi-intervention patent method.